Copenhagen, 23 February 2011 - Today, NeuroSearch announced that the company's
Annual General Meeting will be held on Wednesday 27 April 2011.

Shareholders who wish to have specific issues on the agenda must submit a
written request to the Board of Directors no later than Tuesday 15 March 2011.
Requests must be sent by e-mail to [email protected] or by ordinary post.

Patrik Dahlen
CEO


Contact person:
René Schneider, Executive Vice president, CFO, telephone: +45 4460 8700



About NeuroSearch
NeuroSearch A/S is a European based biopharmaceutical company, specialising in
CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a
pipeline of speciality CNS drugs, including the lead product Huntexil®
(pridopidine), a unique orphan drug in Phase III for the treatment of
Huntington's disease. NeuroSearch is building commercial competences with a
view to commercialising Huntexil® through an in-house marketing and sales
organisation.

NeuroSearch has a well-established drug discovery division, NsDiscovery, with
unique capabilities in the field of ion channels and monoamine transporters.
The company has strategic drug discovery and development alliances with Janssen
Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott.
NeuroSearch also has equity interests in a number of private companies in the
Life Science industry.